Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Operating Leases (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Operating Leases for 5 consecutive years, with $6.8 million as the latest value for Q1 2023.

  • On a quarterly basis, Operating Leases fell 41.68% to $6.8 million in Q1 2023 year-over-year; TTM through Mar 2023 was $6.8 million, a 41.68% decrease, with the full-year FY2022 number at $7.0 million, down 37.42% from a year prior.
  • Operating Leases was $6.8 million for Q1 2023 at Marker Therapeutics, down from $7.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $12.2 million in Q1 2021 to a low of $280247.0 in Q4 2019.
  • A 5-year average of $7.4 million and a median of $9.0 million in 2020 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 4134.99% in 2020, then tumbled 41.68% in 2023.
  • Marker Therapeutics' Operating Leases stood at $280247.0 in 2019, then skyrocketed by 4134.99% to $11.9 million in 2020, then fell by 5.23% to $11.2 million in 2021, then crashed by 37.42% to $7.0 million in 2022, then fell by 3.06% to $6.8 million in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Operating Leases are $6.8 million (Q1 2023), $7.0 million (Q4 2022), and $7.2 million (Q3 2022).